intravenous remifentanil analgesia during labor and decreasing maternal respiratory depression with mosaprid

intravenous remifentanil analgesia during labor and decreasing maternal respiratory depression with mosaprid - remifentanil analgesia during labor and decreasing maternal respiratory depression with mosaprid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021322

Enrollment

150

Registered

2016-04-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain of labor

Interventions

mosaprid administration mosaprid 5mg per every 4 hours during first labor phase no treatment

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: pregnant women who wish to relief labor pain patient obtained a consent with this study

Exclusion criteria

Exclusion criteria: Patients who can not consent. Patient information can not be obtained necessary for analysis. Patients of less than 22 weeks of pregnancy the fetus is alive. Patients with a merger or a history of a high degree of hypersensitivity reactions to other drugs. Patients with impaired consciousness.

Design outcomes

Primary

Measure	Time frame
pain control, the presence or absence of maternal respiratory depression	—

Secondary

Measure	Time frame
Drug administration time, drug bolus administration number of times, the presence or absence of labor induction, patient satisfaction, final delivery mode, Apgar score, the presence or absence of umbilical cord arterial blood pH, birth weight, neonatal complications	—

Countries

Japan

Contacts

Public ContactShingo Io

Kyoto University Department of Gynecology and Obstetrics

shinio@kuhp.kyoto-u.ac.jp075-751-3269

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026